{{Rsnum
|rsid=1273516
|Gene=CYP4F23P
|Chromosome=19
|position=15566899
|Orientation=plus
|GMAF=0.3834
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 18.6 | 50.4 | 31.0
| HCB | 20.4 | 45.3 | 34.3
| JPT | 13.3 | 54.0 | 32.7
| YRI | 19.7 | 44.2 | 36.1
| ASW | 12.3 | 43.9 | 43.9
| CHB | 20.4 | 45.3 | 34.3
| CHD | 18.3 | 48.6 | 33.0
| GIH | 23.0 | 52.0 | 25.0
| LWK | 20.0 | 41.8 | 38.2
| MEX | 6.9 | 27.6 | 65.5
| MKK | 21.8 | 49.4 | 28.8
| TSI | 19.6 | 41.2 | 39.2
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=22491018
|Trait=None
|Title=Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.
|RiskAllele=
|Pval=9E-7
|OR=4.2600
|ORtxt=None
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}